Immunic (IMUX) Q2 Loss Widens 25%
(NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by meaningful clinical progress for its lead product candidate but also persistent financial challenges. There was no revenue reported, consistent with its pre-commercial status. Overall, the period reflected operational headway in drug development but a continued need for capital to fund ongoing trials.
Source: Analyst estimates for the quarter provided by FactSet.
Immunic is a clinical-stage biotechnology company. It is primarily developing therapies for chronic inflammatory and autoimmune diseases. Its most advanced program is focused on multiple sclerosis, a disabling neurological condition that affects millions worldwide.
Source Fool.com
Immunic Inc. Aktie
Absolute Beliebtheit: Immunic Inc. hat nur Buy-Einschätzungen.
Die Community erwartet für Immunic Inc. ein Kursziel von 6 €, was den aktuellen Kurs von 1.0 € mehr als verdoppeln würde.
